Role of the tumor stroma in resistance to anti-angiogenic therapy

Elisabeth J. M. Huijbers; Judy R. van Beijnum; Victor L. Thijssen; Siamack Sabrkhany; Patrycja Nowak-Sliwinska; Arjan W. Griffioen

doi:10.1016/j.drup.2016.02.002

Role of the tumor stroma in resistance to anti-angiogenic therapy

Elisabeth J. M. Huijbers, Judy R. van Beijnum, Victor L. Thijssen, Siamack Sabrkhany, Patrycja Nowak-Sliwinska, Arjan W. Griffioen^*

^*Corresponding author for this work

Fysiologie

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Several angiogenesis inhibitors are currently used in the clinic for treatment of cancer. While anti-angiogenesis treatment can improve treatment outcome, the overall benefit on patient survival is still rather limited. This is partially explained by intrinsic or acquired resistance of tumor cells to angiostatic drugs. In addition, it has become evident that extrinsic mechanisms are also involved in resistance to angiostatic therapy. Most of these extrinsic mechanisms reside in the tumor stroma, which is composed of different cell types, including endothelial (progenitor) cells, smooth muscle cells, pericytes, (myo)fibroblasts, immune cells and platelets. In the current review, we describe the role of these stromal cells in the resistance to anti-angiogenic drugs and discuss possible strategies to overcome resistance and enhance the efficacy of angiostatic therapy.

Original language	English
Pages (from-to)	26-37
Journal	Drug Resistance Updates
Volume	25
DOIs	https://doi.org/10.1016/j.drup.2016.02.002
Publication status	Published - Mar 2016

Keywords

Angiogenesis
Tumor
Stroma
Anti-angiogenic therapy
Resistance

Access to Document

10.1016/j.drup.2016.02.002

Cite this

@article{1c20d1939d1c49bab1c558a203f59d12,

title = "Role of the tumor stroma in resistance to anti-angiogenic therapy",

abstract = "Several angiogenesis inhibitors are currently used in the clinic for treatment of cancer. While anti-angiogenesis treatment can improve treatment outcome, the overall benefit on patient survival is still rather limited. This is partially explained by intrinsic or acquired resistance of tumor cells to angiostatic drugs. In addition, it has become evident that extrinsic mechanisms are also involved in resistance to angiostatic therapy. Most of these extrinsic mechanisms reside in the tumor stroma, which is composed of different cell types, including endothelial (progenitor) cells, smooth muscle cells, pericytes, (myo)fibroblasts, immune cells and platelets. In the current review, we describe the role of these stromal cells in the resistance to anti-angiogenic drugs and discuss possible strategies to overcome resistance and enhance the efficacy of angiostatic therapy. ",

keywords = "Angiogenesis, Tumor, Stroma, Anti-angiogenic therapy, Resistance",

author = "Huijbers, {Elisabeth J. M.} and {van Beijnum}, {Judy R.} and Thijssen, {Victor L.} and Siamack Sabrkhany and Patrycja Nowak-Sliwinska and Griffioen, {Arjan W.}",

year = "2016",

month = mar,

doi = "10.1016/j.drup.2016.02.002",

language = "English",

volume = "25",

pages = "26--37",

journal = "Drug Resistance Updates",

issn = "1368-7646",

publisher = "Elsevier",

}

TY - JOUR

T1 - Role of the tumor stroma in resistance to anti-angiogenic therapy

AU - Huijbers, Elisabeth J. M.

AU - van Beijnum, Judy R.

AU - Thijssen, Victor L.

AU - Sabrkhany, Siamack

AU - Nowak-Sliwinska, Patrycja

AU - Griffioen, Arjan W.

PY - 2016/3

Y1 - 2016/3

N2 - Several angiogenesis inhibitors are currently used in the clinic for treatment of cancer. While anti-angiogenesis treatment can improve treatment outcome, the overall benefit on patient survival is still rather limited. This is partially explained by intrinsic or acquired resistance of tumor cells to angiostatic drugs. In addition, it has become evident that extrinsic mechanisms are also involved in resistance to angiostatic therapy. Most of these extrinsic mechanisms reside in the tumor stroma, which is composed of different cell types, including endothelial (progenitor) cells, smooth muscle cells, pericytes, (myo)fibroblasts, immune cells and platelets. In the current review, we describe the role of these stromal cells in the resistance to anti-angiogenic drugs and discuss possible strategies to overcome resistance and enhance the efficacy of angiostatic therapy.

AB - Several angiogenesis inhibitors are currently used in the clinic for treatment of cancer. While anti-angiogenesis treatment can improve treatment outcome, the overall benefit on patient survival is still rather limited. This is partially explained by intrinsic or acquired resistance of tumor cells to angiostatic drugs. In addition, it has become evident that extrinsic mechanisms are also involved in resistance to angiostatic therapy. Most of these extrinsic mechanisms reside in the tumor stroma, which is composed of different cell types, including endothelial (progenitor) cells, smooth muscle cells, pericytes, (myo)fibroblasts, immune cells and platelets. In the current review, we describe the role of these stromal cells in the resistance to anti-angiogenic drugs and discuss possible strategies to overcome resistance and enhance the efficacy of angiostatic therapy.

KW - Angiogenesis

KW - Tumor

KW - Stroma

KW - Anti-angiogenic therapy

KW - Resistance

U2 - 10.1016/j.drup.2016.02.002

DO - 10.1016/j.drup.2016.02.002

M3 - Article

C2 - 27155374

SN - 1368-7646

VL - 25

SP - 26

EP - 37

JO - Drug Resistance Updates

JF - Drug Resistance Updates

ER -